Provided by Tiger Trade Technology Pte. Ltd.

Incyte

90.78
-2.1700-2.33%
Post-market: 90.50-0.2800-0.31%18:18 EDT
Volume:4.39M
Turnover:399.69M
Market Cap:18.07B
PE:14.16
High:93.34
Open:92.81
Low:90.34
Close:92.95
52wk High:112.29
52wk Low:53.56
Shares:199.01M
Float Shares:163.04M
Volume Ratio:2.72
T/O Rate:2.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.41
EPS(LYR):6.41
ROE:29.87%
ROA:13.57%
PB:3.50
PE(LYR):14.16

Loading ...

Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte

TIPRANKS
·
Mar 07

Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion

TIPRANKS
·
Mar 07

BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing

Reuters
·
Mar 07

Incyte - FDA Issues Complete Response Letter for Zynyz Sbla in Nsclc - SEC Filing

THOMSON REUTERS
·
Mar 07

Incyte - Crl Cites Catalent Indiana Regulatory Compliance as Sole Approvability Issue - SEC Filing

THOMSON REUTERS
·
Mar 07

FDA issues Complete Response Letter for Incyte’s Zynyz NSCLC sBLA over Catalent Indiana compliance findings

Reuters
·
Mar 07

Incyte announces European Commission approval of Zynyz

TIPRANKS
·
Mar 07

European Commission approves Incyte’s Zynyz plus chemotherapy for first-line advanced SCAC

Reuters
·
Mar 07

Incyte Announces the European Commission Approval of Zynyz® (Retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (Scac)

THOMSON REUTERS
·
Mar 07

Guggenheim Remains a Buy on Incyte (INCY)

TIPRANKS
·
Mar 06

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Mar 06

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Incyte (INCY)

TIPRANKS
·
Mar 06

Incyte Is Maintained at In-Line by Evercore ISI Group

Dow Jones
·
Mar 05

Evercore ISI Adjusts Price Target on Incyte to $110 From $73, Maintains In Line Rating

MT Newswires Live
·
Mar 05

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Mar 03

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 28

Eli Lilly, Incyte: EMA’s CHMP issues positive opinion for Olumiant

TIPRANKS
·
Feb 27

Syndax Q4 net loss attributable to common stockholders totals USD 68.0 million, or USD 0.78 per share, narrowing 29.1%

Reuters
·
Feb 27

Argus Adjusts Price Target on Incyte to $115 From $100, Maintains Buy Rating

MT Newswires Live
·
Feb 26

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Feb 26